chromium has been researched along with sirolimus in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (88.46) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, GH; Shen, XD; Song, MF; Yang, Y; Yi, ZW; Zhang, ZQ; Zhu, YF | 1 |
| Barry, JJ; Casey, MA; Feygin, JM; Huibregtse, BA; Pennington, DE; Soucy, NV; Tunstall, R | 1 |
| Allocco, DJ; Dawkins, KD; El-Jack, S; Meredith, IT; Scott, D; Starzyk, RM; Stone, GW; Teirstein, PS; Whitbourn, R; Zambahari, R | 1 |
| Calais, F; Carlsson, J; Götberg, M; James, S; Lagerqvist, B; Nilsson, J; Nilsson, T; Olivecrona, G; Sarno, G; Sjögren, I | 1 |
| Cha, KS; Chae, IH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, SH; Kim, HS; Kim, S; Kwon, HM; Lee, SP; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, JJ; Park, KW; Park, TH; Rhew, JY; Shin, ES; Yoon, JH | 1 |
| Büttner, HJ; Gick, M; Leibundgut, G; Löffelhardt, N; Neumann, FJ; Toma, A; Valina, C | 1 |
| Ge, J; Ge, L; Qian, J; Zhang, F; Zhou, J | 1 |
| Domb, AJ; Farah, S; Khan, W | 1 |
| Allocco, DJ; Cannon, LA; Dawkins, KD; Dens, J; Dubois, CL; Feldman, RL; Lee, TC; Meredith, IT; Mooney, MR; Pompili, VJ; Rabinowitz, AC; Saito, S; Stone, GW; Teirstein, PS | 1 |
| Brugaletta, S; Cequier, A; de Belder, A; de la Torre Hernandez, JM; Eberli, F; Ferrante, G; Galatius, S; Kaiser, C; Sabaté, M; Serruys, PW; Valgimigli, M | 1 |
| Abbott, JD; Srour, JF | 1 |
| Chang, GR; Chiu, YS; Hou, PH; Lin, YC; Mao, FC; Wu, YY | 1 |
| Hu, ZY; Iqbal, J; Pan, DR; Pang, S; Tian, NL; Wu, W; Xu, B; Zhang, YJ; Zhu, H | 1 |
| Allocco, DJ; Amjadi, N; Caputo, C; Christen, T; Dawkins, KD; Kandzari, DE; Rowe, SK; Tamboli, HP; Williams, J | 1 |
| Ge, J; Ge, L; Qian, J; Yang, J; Zhang, F; Zhou, J | 1 |
| Asano, T; de Winter, RJ; Dijkstra, J; Jonker, H; Katagiri, Y; Kimura, T; Kozuma, K; Miyazaki, Y; Onuma, Y; Popma, JJ; Serruys, PW; Sotomi, Y; Stone, GW; Tanabe, K; Tenekecioglu, E; Wykrzykowska, JJ | 1 |
| Allocco, DJ; Chen, J; Dawkins, KD; Fu, G; Han, Y; Hong, T; Jiang, T; Li, H; Liu, H; Pang, W; Su, X; Sun, F; Wang, H; Xu, K; Yang, Y; Yuan, Z; Zhang, J; Zhang, M | 1 |
| Bil, J; Gil, RJ; Kern, A; Pawłowski, T | 1 |
| Anderson, R; Asano, T; Baumbach, A; Johnson, T; Kiemeneij, F; Lansky, AJ; Onuma, Y; Serruys, PW; Slagboom, T; Van Royen, N; Vlachojannis, G; Wijns, W; Xu, B; Zheng, M | 1 |
| Bedair, TM; Han, DK; Joung, YK; Min, IJ; Park, W | 1 |
| Bil, J; Gąsior, M; Gil, RJ; Kern, A; Legutko, J; Lesiak, M; Pawłowski, T; Witkowski, A | 1 |
| Cha, KS; Chae, IH; Hur, SH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, J; Kim, CH; Kim, HS; Kim, S; Kwon, HM; Lee, BR; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, KW; Park, TH; Park, YW; Rhew, JY; Ryu, JK; Shin, ES; Yoon, JH | 1 |
| Aoki, J; Awata, M; Kashiwabara, K; Kimura, T; Kozuma, K; Matsuyama, Y; Nanasato, M; Oba, K; Shinozaki, T; Shiode, N; Tanabe, K; Yamaguchi, J | 1 |
| Asano, T; Chichareon, P; Digne, F; Gil, RJ; Kogame, N; Lefèvre, T; Legutko, J; Modolo, R; Morel, MA; Onuma, Y; Serruys, PW | 1 |
| Pavithran, S; Rajendran, M; Ramasamy, R; Sivakumar, K; Sonawane, B | 1 |
| Collet, C; De Bruyne, B; Karjalainen, PP; Nammas, W; Sia, J | 1 |
2 review(s) available for chromium and sirolimus
| Article | Year |
|---|---|
Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis.
Topics: Chromium; Cobalt; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Humans; Myocardial Infarction; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2014 |
Cobalt chromium-based biodegradable polymer sirolimus-eluting stent: rationale, evidence and clinical experience.
Topics: Chromium; Cobalt; Coronary Artery Disease; Drug Liberation; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Polymers; Prosthesis Design; Sirolimus; Thrombosis | 2015 |
9 trial(s) available for chromium and sirolimus
| Article | Year |
|---|---|
The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.
Topics: Angioplasty, Balloon, Coronary; Chromium; Chromium Alloys; Coronary Stenosis; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Humans; Platelet Aggregation Inhibitors; Platinum; Prospective Studies; Prosthesis Design; Republic of Korea; Research Design; Single-Blind Method; Sirolimus; Time Factors; Treatment Outcome | 2012 |
Two-year clinical outcomes of patients with the second-generation cobalt-chromium sirolimus-eluting stents from the real-world FOCUS registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Cobalt; Cohort Studies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Registries; Sirolimus; Time Factors; Treatment Outcome | 2013 |
Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
Topics: Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Japan; Male; Middle Aged; New Zealand; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Sirolimus; Time Factors; Treatment Outcome; United States | 2015 |
A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study.
Topics: Adolescent; Adult; Aged; China; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Polymers; Sirolimus; Treatment Outcome; Young Adult | 2017 |
Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic le
Topics: Atherosclerosis; Chromium; Cobalt; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Europe; Humans; Neointima; Prospective Studies; Prosthesis Design; Sirolimus; Stents; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent.
Topics: Acute Coronary Syndrome; Chromium; Cobalt; Coronary Stenosis; Drug-Eluting Stents; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Research Design; Self Expandable Metallic Stents; Sirolimus; Treatment Outcome | 2019 |
Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.
Topics: Aged; Chromium; Chromium Alloys; Coronary Angiography; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Failure; Sirolimus | 2019 |
Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study.
Topics: Chromium; Cobalt; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Stents; Treatment Outcome | 2020 |
Comparative study of neointimal coverage between titanium-nitric oxide-coated and everolimus-eluting stents in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Chromium; Coronary Vessels; Drug-Eluting Stents; Everolimus; Humans; Nitric Oxide; Percutaneous Coronary Intervention; Sirolimus; Titanium; Tomography, Optical Coherence; Treatment Outcome | 2023 |
15 other study(ies) available for chromium and sirolimus
| Article | Year |
|---|---|
Sema 3A as a biomarker of the activated mTOR pathway during hexavalent chromium-induced acute kidney injury.
Topics: Acute Kidney Injury; Animals; Biomarkers; Cell Line; Cell Survival; Chromium; Disease Models, Animal; Humans; Kidney Function Tests; Kidney Tubules, Proximal; Male; Oxidative Stress; Rats, Sprague-Dawley; Semaphorin-3A; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2018 |
Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating.
Topics: Angioplasty, Balloon, Coronary; Animals; Chromium; Coronary Vessels; Drug-Eluting Stents; Endothelial Cells; Everolimus; Female; Immunosuppressive Agents; Metals; Microscopy, Electron, Scanning; Platelet Endothelial Cell Adhesion Molecule-1; Platinum; Prosthesis Design; Rabbits; Sirolimus; Stents | 2010 |
PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platinum; Prospective Studies; Sirolimus; Ultrasonography, Interventional | 2011 |
Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platinum; Registries; Sirolimus; Sweden; Treatment Outcome | 2013 |
Longitudinal compression of the platinum-chromium everolimus-eluting stent during coronary implantation: predisposing mechanical properties, incidence, and predictors in a large patient cohort.
Topics: Aged; Cardiovascular Agents; Chi-Square Distribution; Chromium; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Equipment Failure Analysis; Everolimus; Female; Humans; Logistic Models; Male; Materials Testing; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stress, Mechanical; Tomography, Optical Coherence; Treatment Outcome | 2013 |
Crystalline coating of rapamycin onto a stent: process development and characterization.
Topics: Chromium; Cobalt; Crystallization; Drug-Eluting Stents; Microscopy, Atomic Force; Powder Diffraction; Sirolimus; Surface Properties; X-Ray Diffraction | 2013 |
Small vessels and long lesions: changing label indications for drug eluting stents.
Topics: Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platinum; Sirolimus | 2015 |
Rapamycin impairs HPD-induced beneficial effects on glucose homeostasis.
Topics: Adipocytes; Adipose Tissue; Animals; Body Weight; Chromium; Dietary Fats; Dietary Proteins; Energy Intake; Fatty Liver; Glucose; Glucose Intolerance; Glucose Tolerance Test; Glucose Transporter Type 4; Homeostasis; Insulin; Insulin Resistance; Male; Mice; Sirolimus | 2015 |
One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]).
Topics: Adult; Aged; Aged, 80 and over; Chromium; Coronary Angiography; Coronary Artery Disease; Device Approval; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Registries; Sirolimus; Time Factors; Treatment Outcome; United States | 2016 |
Comparison of long-term clinical outcomes after the second-generation cobalt-chromium sirolimus-eluting stents implantation in diabetic versus non-diabetic patients: a subgroup analysis from the prospective FOCUS registry.
Topics: Aged; Chromium; Cobalt; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Sirolimus; Treatment Outcome | 2016 |
Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?
Topics: Absorbable Implants; Cardiovascular Agents; Chromium; Cobalt; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Sirolimus | 2017 |
First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Chromium; Cobalt; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Poland; Registries; Sirolimus; Treatment Outcome | 2018 |
Sustained drug release using cobalt oxide nanowires for the preparation of polymer-free drug-eluting stents.
Topics: Alloys; Anti-Infective Agents; Chromium; Cobalt; Delayed-Action Preparations; Drug Liberation; Drug-Eluting Stents; Nanowires; Oxides; Sirolimus | 2018 |
Impact of Residual Stenosis on the Angiographic Edge Restenosis of a Second-Generation Drug-Eluting Stent.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Chromium; Cobalt; Cohort Studies; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Equipment Failure Analysis; Female; Hospitals, University; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Product Surveillance, Postmarketing; Prognosis; Prosthesis Design; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Sirolimus; Survival Analysis; Treatment Outcome | 2019 |
Serum Sirolimus Levels After Implantation of Third Generation Drug Eluting Cobalt Chromium Coronary Stent in Ductus Arteriosus in Neonates with Duct-Dependent Pulmonary Circulation.
Topics: Chromium; Cobalt; Drug-Eluting Stents; Ductus Arteriosus, Patent; Female; Heart Ventricles; Humans; Immunosuppressive Agents; Infant, Newborn; Male; Prospective Studies; Prosthesis Implantation; Pulmonary Atresia; Pulmonary Circulation; Sirolimus; Treatment Outcome; Ventricular Septum | 2020 |